The findings, presented by Vice President of Medical Affairs Sean Caenepeel, utilized mouse xenografts and human live tumor fragments to evaluate the drug daraxonrasib. The platform successfully mirrored cytotoxic effects across both models, confirming that ex vivo testing can reliably translate preclinical results to patient-derived tissues. This expansion follows the American Society of Clinical Oncology’s recent clinical notice, which officially recognized functional precision medicine as a viable path for improving cancer care.

Elephas CEO Maneesh Arora noted that the company is now among the few with evidence supporting functional testing across two major therapeutic classes. With immunotherapy response rates currently limited to roughly 20 percent of patients, the ability to profile live biopsies for both immune checkpoint inhibitors and targeted drugs offers a potential solution to the lack of accurate predictive biomarkers. By preserving the native tumor microenvironment during testing, the elive platform aims to provide clinicians with real-time data to guide individual treatment decisions.